Device Clinical Trial Compliance Hits 10-Year High – FDA’s Marcarelli
This article was originally published in The Gray Sheet
Executive Summary
Compliance with FDA clinical trial rules is at its highest point in a decade, according to new statistics from the device center's Division of Bioresearch Monitoring
You may also be interested in...
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
“For Cause” Inspections Find Galloping Clinical Trial Violation Rate
The violation rate for clinical trial sponsors shot up in fiscal year 2007, hitting a 10-year high, with FDA finding many of the problems during inspections triggered by complaints, according to CDRH
Device Center Says “522” Actions Are Up, But Industry Has No Cause To Worry
FDA's device center is increasingly emphasizing its ability to compel companies to collect specified postmarket surveillance data for marketed devices, according to Susan Gardner, director of the agency's Office of Surveillance & Biometrics